Tjalf Ziemssen Selected Research

opicinumab

12/2018	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.
10/2018	Predictors of response to opicinumab in acute optic neuritis.
3/2017	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tjalf Ziemssen Research Topics

Disease

124	Multiple Sclerosis 12/2024 - 11/2002
46	Relapsing-Remitting Multiple Sclerosis 05/2024 - 09/2008
10	Infections 03/2024 - 04/2011
8	Inflammation (Inflammations) 03/2024 - 12/2009
7	Disease Progression 11/2022 - 06/2016
6	Fatigue 01/2023 - 09/2008
6	Chronic Progressive Multiple Sclerosis 01/2023 - 01/2017
6	Progressive Multifocal Leukoencephalopathy 02/2022 - 04/2011
5	Parkinson Disease (Parkinson's Disease) 03/2024 - 01/2017
5	Stroke (Strokes) 01/2024 - 02/2007
4	COVID-19 12/2024 - 01/2022
4	Nervous System Diseases (Neurological Disorders) 04/2024 - 05/2015
4	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 04/2011
3	Dementia (Dementias) 02/2024 - 01/2021
3	Lymphopenia (Lymphocytopenia) 10/2023 - 01/2018
3	Hepatolenticular Degeneration (Wilson's Disease) 06/2023 - 01/2017
3	Cognitive Dysfunction 01/2023 - 01/2021
3	Pain (Aches) 01/2022 - 12/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 12/2011
3	Optic Neuritis (Retrobulbar Neuritis) 12/2018 - 03/2017
3	Hypercholesterolemia 01/2013 - 12/2009
2	Neoplasms (Cancer) 10/2023 - 03/2014
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 01/2021
2	Hypertension (High Blood Pressure) 01/2022 - 12/2011
2	Polyneuropathies (Polyneuropathy) 01/2022 - 05/2015
2	Neuroacanthocytosis 05/2021 - 01/2021
2	Seizures (Absence Seizure) 02/2021 - 07/2011
2	Weight Gain 01/2021 - 10/2018
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2020 - 01/2019
2	Bradycardia 01/2020 - 01/2017
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2019 - 08/2007
2	Pulmonary Arterial Hypertension 07/2019 - 06/2014
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 09/2017
2	Obesity 01/2017 - 12/2009
2	Orthostatic Hypotension (Postural Hypotension) 01/2017 - 02/2010
2	Demyelinating Diseases (Demyelinating Disease) 01/2016 - 11/2005
2	Hyperhomocysteinemia 05/2015 - 05/2015
2	Coronary Artery Disease (Coronary Atherosclerosis) 05/2015 - 06/2014
2	Hyperlipidemias (Hyperlipidemia) 05/2015 - 05/2015
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2009 - 01/2004
1	Obstructive Sleep Apnea 02/2024
1	Neurobehavioral Manifestations 02/2024
1	Hallucinations (Hallucination) 01/2024
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2024

Drug/Important Bio-Agent (IBA)

30	Fingolimod Hydrochloride (FTY720)FDA Link 12/2023 - 12/2013
22	Alemtuzumab (Campath)FDA Link 01/2023 - 01/2015
18	Natalizumab (Tysabri)FDA Link 04/2024 - 09/2010
17	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2016
16	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 11/2002
10	Retinaldehyde (Retinal)IBA 03/2024 - 08/2009
8	Monoclonal AntibodiesIBA 01/2024 - 04/2011
6	Sphingosine-1-Phosphate ReceptorsIBA 10/2022 - 01/2018
5	siponimodIBA 12/2023 - 08/2013
5	diroximel fumarateIBA 12/2023 - 01/2020
4	ofatumumab FDA Link 12/2024 - 01/2022
4	Proteins (Proteins, Gene)FDA Link 11/2023 - 11/2009
4	Cladribine FDA LinkGeneric 10/2023 - 11/2020
4	Interferon beta-1a FDA Link 01/2022 - 01/2017
3	mRNA VaccinesIBA 12/2024 - 12/2022
3	ocrelizumabIBA 04/2024 - 03/2020
3	tau Proteins (tau Protein)IBA 11/2023 - 01/2021
3	TabletsIBA 10/2023 - 01/2020
3	InterferonsIBA 01/2023 - 07/2019
3	laquinimodIBA 04/2022 - 06/2016
3	Dimethyl FumarateIBA 01/2022 - 01/2020
3	AntibodiesIBA 01/2022 - 08/2007
3	Immunoglobulin G (IgG)IBA 01/2022 - 08/2007
3	Complement System Proteins (Complement)IBA 10/2021 - 01/2018
3	FumaratesIBA 01/2021 - 01/2020
3	AutoantibodiesIBA 01/2020 - 08/2007
3	Interferon-betaIBA 07/2019 - 09/2015
3	opicinumabIBA 12/2018 - 03/2017
3	Vasodilator Agents (Vasodilators)IBA 09/2015 - 02/2010
2	ozanimodIBA 12/2023 - 01/2022
2	Glial Fibrillary Acidic ProteinIBA 11/2023 - 01/2023
2	Messenger RNA (mRNA)IBA 01/2023 - 12/2022
2	Phosphopyruvate Hydratase (Enolase)IBA 01/2023 - 10/2022
2	teriflunomideIBA 01/2023 - 01/2022
2	IntegrinsIBA 11/2021 - 01/2017
2	Phosphotransferases (Kinase)IBA 05/2021 - 01/2021
2	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2021 - 07/2016
2	AntigensIBA 01/2020 - 02/2007
2	Phosphates (Orthophosphate)IBA 01/2020 - 01/2018
2	CannabidiolIBA 01/2019 - 01/2019
2	Dronabinol (THC)FDA LinkGeneric 01/2019 - 01/2019
2	Methionine (L-Methionine)FDA Link 05/2015 - 05/2015
2	Bevacizumab (Avastin)FDA Link 05/2013 - 08/2009
2	oxidized low density lipoproteinIBA 11/2010 - 12/2009
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 06/2005 - 11/2002
1	Neutralizing AntibodiesIBA 12/2024

Therapy/Procedure

72	Therapeutics 05/2024 - 11/2002
4	Immunotherapy 01/2024 - 01/2017
4	Blood Component Removal (Apheresis) 12/2019 - 12/2009
3	Aftercare (After-Treatment) 06/2023 - 01/2015
3	Drug Therapy (Chemotherapy) 01/2022 - 05/2013
2	Injections 01/2022 - 12/2015
2	Activities of Daily Living (ADL) 01/2017 - 12/2011
2	Immunomodulation 06/2014 - 02/2007
2	Magnetic Field Therapy 11/2011 - 05/2009
1	Home Nursing (Nursing, Home) 01/2024